Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant human bone morphogenetic protein-2 (rhBMP-2) gel is an experimental topical biologic formulation evaluated by the University of Baghdad for dental applications. rhBMP-2 is a potent osteoinductive growth factor that belongs to the transforming growth factor-beta (TGF-β) superfamily. It functions by binding to specific BMP receptors on the surface of mesenchymal stem cells, triggering a signaling cascade that promotes their differentiation into bone-forming osteoblasts. In the context of partial edentulism, the gel is applied locally to the osteotomy site during dental implant surgery to accelerate osseointegration, improve primary and secondary implant stability, and enhance peri-implant bone density.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant human bone morphogenetic protein-2 gel.